Multiple predictive products developed to meet recognized medical needs in high-potential global markets

• Broadens revenue opportunities
• PREVU* Point of Care (POC) Skin Sterol Test cleared for sale in the U.S., Canada and CE-marked
• Strong clinical validation to date for all products

Effective, low-risk business model

• Focused on already-proven technologies that can be developed into products quickly
• Clinical trials largely funded by third parties, enabling a low cost structure

Strategic relationships with world-leading organizations

• M.D. Anderson Cancer Center; The Cleveland Clinic Foundation; National Heart, Lung and Blood Institute; AtheroGenics, Inc.; U.S. National Cancer Institute; and Montreal Heart Institute

Poised to generate revenue